कंपनी का अवलोकन
Kairos Pharma, Ltd. (KAPA) operates as a clinical-stage biopharmaceutical entity dedicated to the development of novel therapeutics specifically designed for cancer patients. The company's therapeutic portfolio includes the creation of antibodies and small molecules aimed at treating prostate cancer, lung cancer, breast cancer, and glioblastoma, reflecting its focus within the healthcare sector. This firm is categorized under the biotechnology industry, a domain characterized by high innovation requirements and significant regulatory scrutiny for bringing new medical solutions to market. The company currently holds a market capitalization of $11.99M, while its annual revenue and total employee count are not publicly disclosed in the available financial data. This limited market capitalization indicates that Kairos Pharma, Ltd. is a small-cap entity, which typically suggests a younger business stage or one that requires substantial capital to advance its clinical development pipelines before achieving significant commercial scale.
वित्तीय स्वास्थ्य
The financial statements for Kairos Pharma, Ltd. reveal a net income of $-5,447,000 and an EBITDA of $-5,412,000, while the trailing twelve-month revenue figure remains unreported. The substantial gap between the reported revenue status and the negative net income highlights a cost structure where operating expenses and research and development costs significantly exceed current income generation capabilities. The company reports a free cash flow of $-1,632,500, which indicates that the organization is burning cash to fund its operations and clinical trials rather than generating liquidity from daily business activities. All three key profitability metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, a common characteristic for clinical-stage biotechnology firms that have not yet achieved commercial product sales to generate revenue. In terms of liquidity management, the company holds $4.49M in cash and maintains a debt balance of $0, resulting in a debt-to-equity ratio that is not applicable due to the lack of equity or debt data in standard reporting. The current ratio stands at 27.07, a figure that suggests an exceptionally strong short-term liquidity position, meaning the company has ample current assets to cover its short-term liabilities despite its lack of commercial revenue. Furthermore, the return on equity is -98.0% and the return on assets is -56.6%, metrics that reveal the company is currently destroying shareholder value and utilizing its assets inefficiently in terms of generating profit, a typical phase for pre-revenue biotech firms investing heavily in future potential rather than current returns.
मूल्यांकन आकलन
The valuation metrics for Kairos Pharma, Ltd. present a trailing P/E ratio that is not applicable due to negative earnings, while the forward P/E stands at -1.18, a negative figure that implies the market is pricing in future earnings that are currently expected to remain negative. The price-to-book ratio is 1.52, suggesting that the company's market valuation is trading at a premium of 52% over its net book value, which can reflect investor optimism regarding the potential success of its clinical-stage assets. Alternative valuation measures such as the price-to-sales ratio and the EV/EBITDA of -1.39 are provided, where the negative EV/EBITDA confirms that the company's enterprise value is driven more by its asset base and potential than by current earnings power. The stock's trading range over the last 52 weeks spans from a low of $0.40 to a high of $2.11, indicating a high degree of volatility and a wide range of price discovery within the biotechnology sector. The beta value is not available in the current data, preventing a direct comparison of the stock's price volatility relative to the broader market index at this time. These valuation figures collectively paint a picture of a high-risk, high-potential asset that is valued based on future clinical milestones rather than current financial performance.
Growth & Income
The available financial data indicates that both the year-over-year revenue growth and earnings growth rates are not applicable, which is consistent with the company's status as a clinical-stage entity with no commercial revenue history. Since the company does not report positive revenue or earnings growth, there is no divergence between earnings and revenue growth rates to analyze in terms of operational efficiency improvements. As a non-dividend payer, Kairos Pharma, Ltd. reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company does not distribute profits to shareholders because it retains all resources for reinvestment into its drug development programs. Consequently, the company's capital allocation strategy focuses entirely on funding research, development, and clinical trials rather than providing income streams to investors. The overall growth and income profile of Kairos Pharma, Ltd. is defined by a reliance on future product approvals and commercialization success to transition from a cash-burning clinical-stage model to a profitable commercial biotechnology business.